This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk

TEZSPIRE^® (tezepelumab): efficacy & clinical trials

See full indication

TEZSPIRE is the first & only licensed biologic that treats across phenotypes and irrespective of key biomarker levels^1-10

Patients enrolled with high and low key clinical biomarker levels (bEOS, IgE, or FeNO).^1*

Relative Risk Reductions In Exacerbations^2,3

AAER reduction vs placebo^†

TEZSPIRE 0.93 (n=528) vs placebo 2.1 (n=531)
(RR=0.44, 95% CI: 0.37–0.53; P<0.001);

ARR=1.17

 

Primary endpoint of NAVIGATOR

See data

AAER reduction vs placebo in patients with baseline eos <300 cells/µl^†

TEZSPIRE 1.02 (n=309) vs placebo 1.73 (n=309)
 (RR=0.59, 95% CI: 0.46–0.75; P<0.001);

ARR=0.71

  

Primary endpoint of NAVIGATOR

See data

Hospitalisation^2,3

Relative risk reduction in AAER with hospitalisation or ED visit vs placebo

TEZSPIRE 0.06 (n=528) vs placebo 0.28 (n=531)
 (RR=0.21, 95% CI: 0.12–0.37);

ARR=0.22

  

Additional secondary endpoint of NAVIGATOR

See data

Quality of life^2,3

Observed improvements in asthma control, health-related quality of life and asthma symptoms vs placebo

Key secondary endpoints of NAVIGATOR

See data

Lung function^1,2

lung_function_panel_image

130ml LS Mean Difference from Placebo. Lung function improvement was observed at Week 2 and maintained over 52 weeks of treatment.

(230mL improvement with TEZSPIRE at Week 52 compared
with baseline vs 100mL for placebo, 130mL difference;
95% CI: 0.08–0.18; P<0.001)

Key secondary endpoint of NAVIGATOR

See data

*No restrictions across eosinophilic and non-eosinophilic, allergic and non-allergic phenotypes, eosinophils, IgE, and FeNO biomarkers. 
^†,All patients received SOC (MD or HD ICS + additional controller).^1,3

Reductions across key clinical biomarker levels^1,3

Additional secondary endpoint of NAVIGATOR: change from baseline in bEOS, FeNO and IgE³

biomarker_data

Adapted from Menzies-Gow A, et al. NEJM. 2021 (Supplementary)

TEZSPIRE mode of action

Blocking TSLP with TEZSPIRE has been shown to reduce a broad spectrum of  biomarkers and cytokines associated with airway inflammation^1,3

Explore MOA

TEZSPIRE (tezepelumab) is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment¹

AAER=annualised asthma exacerbation rate; ARR=absolute risk reduction; bEOS=blood eosinophils; CI=confidence interval; ED=emergency department; FeNO=fractional exhaled nitric oxide; HD=high dose; ICS=inhaled corticosteroid; IgE=immunoglobulin E; MD=medium dose; MOA=mode of action; RR=rate ratio; SOC=standard of care; TSLP=thymic stromal lymphopoietin.

Tezspire (tezepelumab). Summary of Product Characteristics. 2022. Available at: https://www.medicines.org.uk/emc/product/14064/smpc (last accessed: November 2024).
Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809.
Menzies-Gow A, Corren J, Bourdin A, et al. Supplementary Appendix. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809.
Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946.
Nucala (mepolizumab). Summary of Product Characteristics. 2022. Available at: https://www.medicines.org.uk/emc/product/10563/smpc (last accessed: November 2024).
Cinqaero (reslizumab). Summary of Product Characteristics. 2022. Available at: https://www.medicines.org.uk/emc/product/4370/smpc (last accessed: November 2024).
Fasenra (Benralizumab). Summary of Product Characteristics. 2023. Available at: https://www.medicines.org.uk/emc/product/10559/smpc (last accessed: November 2024).
Dupixent (dupilumab). Summary of Product Characteristics. 2023. Available at: https://www.medicines.org.uk/emc/product/8553/smpc (last accessed: November 2024).
Xolair (omalizumab). Summary of Product Characteristics. 2022. Available at: https://www.medicines.org.uk/emc/product/4725/smpc (last accessed: November 2024).
Corren J et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma: a pooled analysis of the phase 2b PATHWAY and phase 3 NAVIGATOR studies. Poster presented at: AAAAI 2022 (Poster 044).

GB-56753 | November 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.

This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Cookie Policy

TEZSPIRE® (tezepelumab): efficacy & clinical trials

TEZSPIRE is the first & only licensed biologic that treats across phenotypes and irrespective of key biomarker levels1-10

Patients enrolled with high and low key clinical biomarker levels (bEOS, IgE, or FeNO).1*

Relative Risk Reductions In Exacerbations2,3

AAER reduction vs placebo†

ARR=1.17

AAER reduction vs placebo in patients with baseline eos <300 cells/µl†

ARR=0.71

Hospitalisation2,3

Relative risk reduction in AAER with hospitalisation or ED visit vs placebo

ARR=0.22

Quality of life2,3

Observed improvements in asthma control, health-related quality of life and asthma symptoms vs placebo

Lung function1,2

View biomarker data

Reductions across key clinical biomarker levels1,3

Additional secondary endpoint of NAVIGATOR: change from baseline in bEOS, FeNO and IgE3

TEZSPIRE mode of action

Blocking TSLP with TEZSPIRE has been shown to reduce a broad spectrum of biomarkers and cytokines associated with airway inflammation1,3

Abbreviations and References

TEZSPIRE^® (tezepelumab): efficacy & clinical trials

TEZSPIRE is the first & only licensed biologic that treats across phenotypes and irrespective of key biomarker levels^1-10

Patients enrolled with high and low key clinical biomarker levels (bEOS, IgE, or FeNO).^1*

Relative Risk Reductions In Exacerbations^2,3

AAER reduction vs placebo^†

AAER reduction vs placebo in patients with baseline eos <300 cells/µl^†

Hospitalisation^2,3

Quality of life^2,3

Lung function^1,2

Reductions across key clinical biomarker levels^1,3

Additional secondary endpoint of NAVIGATOR: change from baseline in bEOS, FeNO and IgE³

Blocking TSLP with TEZSPIRE has been shown to reduce a broad spectrum of  biomarkers and cytokines associated with airway inflammation^1,3